Table 2. Clinical and pathologic information.
| N | Expression of PD-L1(%) | pa | |||
|---|---|---|---|---|---|
| Negative | Positive | ||||
| Total | 64 | 14 (21.88) | 50 (78.12) | ||
| Gender | 0.183 | ||||
| Male | 33 | 5 (15.15) | 28 (84.85) | ||
| Female | 31 | 9 (29.03) | 22 (70.97) | ||
| Age | 0.580 | ||||
| < 60 | 45 | 9 (20.00) | 36 (80.00) | ||
| ≥ 60 | 19 | 5 (26.32) | 14 (73.68) | ||
| KPS | 0.080 | ||||
| < 80 | 9 | 4 (44.44) | 5 (55.56) | ||
| ≥ 80 | 55 | 10 (18.18) | 45 (81.82) | ||
| WHO Grade | 0.013 | ||||
| LGG | 23 | 9 (39.13) | 14 (60.87) | ||
| PA | 11 | 5 | 6 | ||
| DA | 12 | 4 | 8 | ||
| HGG | 41 | 5 (12.20) | 36 (87.80) | ||
| AA | 13 | 1 | 12 | ||
| GBM | 28 | 4 | 24 | ||
| VEGF | 0.002 | ||||
| Negative | 10 | 6 (60.00) | 4 (40.00) | ||
| Positive | 54 | 8 (14.81) | 46 (85.19) | ||
| MMP-9 | 0.068 | ||||
| Negative | 12 | 5 (41.67) | 7 (58.33) | ||
| Positive | 52 | 9 (17.31) | 43 (82.69) | ||
| Ki-67 | 0.002 | ||||
| Negative | 13 | 7 (53.85) | 6 (46.15) | ||
| Positive | 51 | 7 (13.73) | 44 (86.27) | ||
aThe correlation between PD-L1 expression and clinicopathological features was assessed by Mann–Whitney U test. Abbreviations: LGG, low grade glioma; PA, pilocytic astrocytoma; DA, diffuse astrocytoma; HGG, high grade glioma; AA, anaplastic astrocytoma; GBM, glioblastoma.